Delcath Systems, Inc. s in-depth stock price analysis indicates that the stock price has dropped -89.42% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -94.27% . Looking at the past 52 week period, the stock price is down -94.98% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Delcath Systems, Inc. has a negative value of -80 compared to overall market performance. Delcath Systems, Inc. (NASDAQ:DCTH) has tumbled 31.67% during the past week and has dropped 45.93% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 32.22%. Delcath Systems, Inc. (NASDAQ:DCTH) has underperformed the index by 46.89% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Delcath Systems, Inc. (NASDAQ:DCTH) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.0025 points or 1.13% at $0.219 with 3,715,666 shares getting traded. Post opening the session at $0.23, the shares hit an intraday low of $0.204 and an intraday high of $0.23 and the price was in this range throughout the day. The company has a market cap of $4 million and the number of outstanding shares has been calculated to be 18,125,392 shares. The 52-week high of Delcath Systems, Inc. (NASDAQ:DCTH) is $6.848 and the 52-week low is $0.2.
Company has reported several Insider transactions to the SEC, on Jul 28, 2015, Roger G Phd Stoll (director) purchased 20,000 shares at 0.54 per share price.On Jul 28, 2015, Marco Taglietti (director) purchased 200,000 shares at 0.54 per share price.On Jul 24, 2015, Laura A Philips (director) purchased 162,653 shares at 0.50 per share price.
Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.